The Effects of Beta-Diethylaminoethyl-Diphenylpropylacetate (SKF-525-A) on Sickling in vitro

Beta-diethylaminoethyl-diphenylpropylacetate (SKF-525-A), a surface- active agent, inhibits sickling of erythrocytes from individuals with homozygous sickle cell anemia (SS cells) in vitro. Sickling was prevented when SS cells were incubated in .0003 M SKF-525-A, washed free of excess drug, and then...

Full description

Saved in:
Bibliographic Details
Main Authors: Garry, Vincent F , Jr, Gilman, Priscilla A, Heitkamp, Dale H, Mills, Kenneth
Format: Report
Language:English
Subjects:
ACETATES
AMINES
ANEMIAS
BLOOD DISEASES
CHEMOTHERAPY
DRUGS
ERYTHROCYTES
HEMOGLOBIN
Pharmacology
SICKLE CELL ANEMIA
SICKLE CELLS
SKF-525-A
SURFACE ACTIVE SUBSTANCES
Online Access:Request full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Beta-diethylaminoethyl-diphenylpropylacetate (SKF-525-A), a surface- active agent, inhibits sickling of erythrocytes from individuals with homozygous sickle cell anemia (SS cells) in vitro. Sickling was prevented when SS cells were incubated in .0003 M SKF-525-A, washed free of excess drug, and then deoxygenated in humidified nitrogen atmosphere. Polymerization of sickle hemoglobin and submembrane vesicles could be demonstrated in these cells by electron microscopy. At .0003 M SKF-525-A approximately 10% of the cells lysed. Incubation of pretreated cells at 37C without added oxygen for 24 hours did not produce significant additional lysis. Irreversibly sickled cells were unaffected by drug treatment. Preliminary studies suggest that the oxygen affinity of sickle hemoglobin in the intact cell is not altered by SKF-525-A. It is hypothesized that inhibition of sickling is the result of drug-induced alterations of the cell membrane.